FDA Panel Backs Approval Of Orexigen's Obesity Drug Contrave
This article was originally published in The Pink Sheet Daily
Executive Summary
Promised post-market randomized clinical trial to assess cardiovascular risk tips the panel in favor of the naltrexone/bupropion combination.